A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or issues, but a greater risk of 19 others.
Articles on GLP-1 agonist drugs
Displaying all articles
Clinical trials show that around one in ten people are ‘non-responders’. Outside of trials, that figure might be much higher.
Berberine, green tea extract and taurine are just some of the ingredients advertised as being able to ‘boost’ GLP-1 levels.
A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares with Ozempic.
The sellers of these online products acknowledge that many of their drugs are for ‘research purposes only’ or ‘not for human consumption.’
Patents for a drug related to Ozempic have expired, so pharmaceutical companies are working to develop ‘generic’ versions. These are likely to be much cheaper. But how do they compare with Ozempic?
Top contributors
-
ARC Future Fellow, School of Biomedical Sciences, The University of Queensland
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Head of the Translational Nanomedicine & Biotherapeutics Group and Senior Research Fellow, Adelaide University
-
Accredited Pharmacist, PhD Student, Adelaide University
-
Honorary Associate Professor, University of Leicester
-
Associate Professor of Physiology and Medical Education, Anglia Ruskin University
-
Professor of Community Health and Wellbeing, The University of Queensland
-
Accredited Practising Dietitian and Lecturer, Southern Cross University